Source: International Congress 2015 – Asthma: emerging risk factors and current management of the patient
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Kian Fan Chung (London, United Kingdom). Targeting the interleukin pathway in the treatment of asthma. International Congress 2015 – Asthma: emerging risk factors and current management of the patient

Member's Comments

No comment yet.

Related content which might interest you: Cytokines in asthma Source: Eur Respir J 2001; 18: 24S-33S Year: 2001 The investigation of the role of interleukin (IL)-17 in COPD and asthma Source: Eur Respir J 2005; 26: Suppl. 49, 442s Year: 2005 Intermittent hypoxia activates the Interleukin (IL)-1ß and nuclear factor (NF)?B signaling pathway in primary murine macrophages Source: International Congress 2019 – Insights into the pathophysiology of sleep-disordered breathing Year: 2019 Interleukin-17 cytokine signalling in patients with asthma Source: Eur Respir J 2014; 44: 1319-1331 Year: 2014 Induction of denitrase by interleukin 1β Source: Eur Respir J 2005; 26: Suppl. 49, 98s Year: 2005 Activation of IL-32 pathway in COPD Source: Annual Congress 2008 - Cell biology of asthma and COPD Year: 2008 Interleukin-18 and interleukin-18 receptor-? expression in allergic asthma Source: Eur Respir J 2011; 38: 981-983 Year: 2011 Interleukin 10 regulates airway remodeling through the TGF-β signaling Source: Eur Respir J 2005; 26: Suppl. 49, 585s Year: 2005 Expression of interleukin-4 receptor in bronchial asthma patients treated with specific immunotherapy (SIT) Source: Eur Respir J 2002; 20: Suppl. 38, 589s Year: 2002 Suppressor of cytokine signalling 1 (SOCS1) and asthma exacerbations Source: International Congress 2018 – Mechanisms of respiratory infection Year: 2018 Analysis of cytokine signaling pathway JAK-STAT through their activation in patients with asthma Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology Year: 2008 Role of interferon-gamma as a marker of asthma severity and control Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019 Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma Source: Eur Respir Rev 2009; 19: 46-54 Year: 2010 Analysis of cytokine signaling through the STAT6 activation in patients with atopic steroid-free asthma Source: Annual Congress 2007 - New mechanisms in the pathogenesis of asthma and allergy Year: 2007 Reduced expression of interferon stimulated genes in refractory asthma Source: Annual Congress 2012 - Cell biology and inflammatory gene expression in chronic lung disease Year: 2012 Role of interleukin 6 in COPD patients over nine years Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020 New anti-asthma therapies: suppression of the effect of interleukin (IL)-4 and IL-5 Source: Eur Respir J 2001; 17: 499-506 Year: 2001 Use of interleukin-1beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1Ra) contents in alveolar macrophages for estimation of inflammation activity in patients with different levels of asthma control Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection Year: 2013 Cytokine modulators as novel therapies for airway disease Source: Eur Respir J 2001; 18: 67S-77S Year: 2001 IL-5/IL-13 drive NLRP3 inflammasome-mediated, steroid-resistant AHR in a model of obesity-associated asthma Source: International Congress 2019 – Understanding the mechanisms underlying airway diseases Year: 2019